8-Fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-6h-pyrrolo[4,3,2-ef][2]benzazepin-6-one
| Title | Journal |
|---|---|
| Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. | Lancet (London, England) 20171028 |
| Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. | The Lancet. Oncology 20170101 |
| Evaluation of rucaparib and companion diagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy. | Future oncology (London, England) 20160601 |
| Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer. | British journal of cancer 20160329 |
| An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma. | BMC cancer 20160101 |
| Identification of potent Yes1 kinase inhibitors using a library screening approach. | Bioorganic & medicinal chemistry letters 20130801 |
| Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. | Cancer discovery 20120901 |
| Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition. | Nature medicine 20110701 |
| Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699. | British journal of cancer 20101109 |
| Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors. | Clinical cancer research : an official journal of the American Association for Cancer Research 20100415 |
| Poly(adp-ribose) polymerase inhibitors: a novel drug class with a promising future. | Cancer journal (Sudbury, Mass.) 20100101 |
| Emergence of rationally designed therapeutic strategies for breast cancer targeting DNA repair mechanisms. | Breast cancer research : BCR 20100101 |
| Vasoactivity of AG014699, a clinically active small molecule inhibitor of poly(ADP-ribose) polymerase: a contributory factor to chemopotentiation in vivo? | Clinical cancer research : an official journal of the American Association for Cancer Research 20091001 |
| Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma. | Clinical cancer research : an official journal of the American Association for Cancer Research 20090215 |
| Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. | Clinical cancer research : an official journal of the American Association for Cancer Research 20081201 |
| Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial. | Molecular cancer therapeutics 20070301 |
| Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. | Journal of the National Cancer Institute 20040107 |
| Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. | Clinical cancer research : an official journal of the American Association for Cancer Research 20000701 |